PFIZER Australia has advised
healthcare professionals that its
Cycloblastin (cyclophaphamaide)
50mg x 50 tablets are being
discontinued effective from 01 Oct.
“The product is being
discontinued because the
manufacturer has advised that they
are not able to produce the product
any longer...there is no safety,
quality nor efficacy concern in
relation to this product,” Pfizer said
in a letter earlier this month.
Cycloblastin is indicated for the
treatment of a range of neoplastic
conditions, autoimmune diseases
and immunotherapies and for the
treatment of transplant rejection.
It’s the only oral formulation on
the market, with clinicians advised
to review their current patients and
develop a transition plan to avoid
reliance on Cycloblastin beyond the
beginning of October this year.
Alternative therapies include
intravenous cyclophosphamide - for
further details call 1800 629 921.The above article was sent to subscribers in Pharmacy Daily's issue from 29 Apr 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Apr 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.